Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE.

Leuk Lymphoma. 2018 Nov;59(11):2595-2601. doi: 10.1080/10428194.2018.1443330. Epub 2018 Apr 4.

2.

IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.

Mazharuddin S, Chattopadhyay A, Levy MY, Redner RL.

Leuk Lymphoma. 2018 Sep;59(9):2246-2249. doi: 10.1080/10428194.2017.1421761. Epub 2018 Jan 19. No abstract available.

3.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL.

Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. Epub 2017 Aug 30.

PMID:
28864289
4.

Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.

Lontos K, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Gooding WE, Humar A, Boyiadzis M.

Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13052. Epub 2017 Aug 9.

PMID:
28710776
5.

Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.

Lim MJ, Agha A, Im A, Raptis A, Hou JZ, Boyiadzis M, Sehgal AR, Redner RL, Dorritie K, Marks SS, Agha ME, Lim SH.

Hematol Oncol. 2018 Apr;36(2):495-497. doi: 10.1002/hon.2456. Epub 2017 Jun 30. No abstract available.

PMID:
28664979
6.

Leukapheresis in patients newly diagnosed with acute myeloid leukemia.

Villgran V, Agha M, Raptis A, Hou JZ, Farah R, Lim SH, Redner RL, Im A, Sehgal A, Dorritie KA, Kiss JE, Normolle D, Boyiadzis M.

Transfus Apher Sci. 2016 Oct;55(2):216-220. doi: 10.1016/j.transci.2016.07.001. Epub 2016 Jul 14.

PMID:
27470709
7.

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.

Im A, Amjad A, Agha M, Raptis A, Hou JZ, Farah R, Lim S, Sehgal A, Dorritie KA, Redner RL, McLaughlin B, Shuai Y, Duggal S, Boyiadzis M.

Oncol Res. 2016;24(2):73-80. doi: 10.3727/096504016X14586627440156.

PMID:
27296947
8.

The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.

Swaney EM, Chattopadhyay A, Abecassis I, Rush EA, Redner RL.

Leuk Lymphoma. 2016 Aug;57(8):1933-7. doi: 10.3109/10428194.2015.1124992. Epub 2016 Jan 12.

9.

Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia.

Soni A, Djokic M, Hou JZ, Redner RL, Boyiadzis M.

Leuk Lymphoma. 2015;56(11):3236-9. doi: 10.3109/10428194.2015.1036262. Epub 2015 May 20. Review. No abstract available.

PMID:
25860246
10.

NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

Chattopadhyay A, Abecassis I, Redner RL.

Leuk Lymphoma. 2015;56(12):3401-3406. doi: 10.3109/10428194.2015.1023799. Epub 2015 Oct 5.

11.

Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia.

Ross K, Gillespie-Twardy AL, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, Lin Y, Boyiadzis M.

Oncol Res. 2015;22(2):85-92. doi: 10.3727/096504014X14146137738547.

PMID:
25706395
12.

An ATRActive future for differentiation therapy in AML.

Johnson DE, Redner RL.

Blood Rev. 2015 Jul;29(4):263-8. doi: 10.1016/j.blre.2015.01.002. Epub 2015 Jan 21.

13.

Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD.

Chattopadhyay A, Hood BL, Conrads TP, Redner RL.

Mol Cancer Res. 2014 Sep;12(9):1283-91. doi: 10.1158/1541-7786.MCR-14-0080. Epub 2014 Jul 17.

14.

STAT transcription factors in normal and cancer stem cells.

Dorritie KA, Redner RL, Johnson DE.

Adv Biol Regul. 2014 Sep;56:30-44. doi: 10.1016/j.jbior.2014.05.004. Epub 2014 Jun 5. Review.

PMID:
24931719
15.

Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade.

Rush EA, Pollock SL, Abecassis I, Redner RL.

Leuk Res. 2013 Dec;37(12):1704-10. doi: 10.1016/j.leukres.2013.09.024. Epub 2013 Sep 29.

16.

NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation.

Pollock SL, Rush EA, Redner RL.

Leuk Lymphoma. 2014 Jun;55(6):1383-7. doi: 10.3109/10428194.2013.830303. Epub 2013 Sep 18.

PMID:
23927396
17.

PRAMEing a picture of differentiation therapy for AML?

Redner RL.

Clin Cancer Res. 2013 May 1;19(9):2277-9. doi: 10.1158/1078-0432.CCR-13-0386. Epub 2013 Mar 26.

18.

Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.

Raval JS, Redner RL, Kiss JE.

J Clin Apher. 2013 Aug;28(4):321-4. doi: 10.1002/jca.21254. Epub 2013 Mar 1.

PMID:
23450778
19.

Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

Mehta DR, Foon KA, Redner RL, Raptis A, Agha M, Hou JZ, Duggal S, Luong TM, Schlesselman JJ, Boyiadzis M.

Leuk Res. 2011 Jul;35(7):885-8. doi: 10.1016/j.leukres.2010.12.030. Epub 2011 Feb 18.

PMID:
21315448
20.

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.

Boyiadzis M, Redner RL, Raptis A, Hou JZ, Agha M, Foon KA.

Ann Hematol. 2011 Jun;90(6):733-5. doi: 10.1007/s00277-010-1076-0. Epub 2010 Sep 21. No abstract available.

PMID:
20857113
21.

Cryptic insertion of PML-RARA into the 3p25 locus in an acute promyelocytic leukemia with t(3;17)(p25;q21).

Chattopadhyay A, Redner RL.

Cancer Genet Cytogenet. 2010 Aug;201(1):28-31. doi: 10.1016/j.cancergencyto.2010.05.001.

22.

Knee pain: ACL, MCL, or CML?

Novelli EM, Redner RL.

Blood. 2010 Jul 1;115(26):5287. No abstract available.

PMID:
20614568
23.

Why doesn't imatinib cure chronic myeloid leukemia?

Redner RL.

Oncologist. 2010;15(2):182-6. doi: 10.1634/theoncologist.2009-0297. Epub 2010 Feb 2. Review.

24.

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.

Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE.

J Clin Oncol. 2010 Feb 20;28(6):1047-53. doi: 10.1200/JCO.2009.25.5158. Epub 2010 Jan 19.

25.

Dasatinib promotes ATRA-induced differentiation of AML cells.

Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE.

Leukemia. 2010 Mar;24(3):663-5. doi: 10.1038/leu.2009.267. Epub 2009 Dec 24. No abstract available.

PMID:
20033056
26.

Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.

McHayleh W, Sehgal R, Redner RL, Raptis A, Agha M, Natale J, Luong TM, Schlesselman JJ, Foon KA, Boyiadzis M.

Leuk Lymphoma. 2009 Nov;50(11):1848-53. doi: 10.3109/10428190903216788.

PMID:
19860628
27.

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.

Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, Redner RL, Miller BM, Beumer JH.

Br J Clin Pharmacol. 2009 Sep;68(3):370-4. doi: 10.1111/j.1365-2125.2009.03466.x.

28.

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR.

Br J Haematol. 2009 Feb;144(3):409-15. doi: 10.1111/j.1365-2141.2008.07464.x. Epub 2008 Nov 11.

PMID:
19016720
29.

Effect of antacid on imatinib absorption.

Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH.

Cancer Chemother Pharmacol. 2009 Feb;63(3):525-8. doi: 10.1007/s00280-008-0778-7. Epub 2008 May 24.

30.

Gefitinib potentiates myeloid cell differentiation by ATRA.

Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE.

Leukemia. 2008 Aug;22(8):1624-7. doi: 10.1038/leu.2008.28. Epub 2008 Feb 28. No abstract available.

31.

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL.

Lancet. 2008 Feb 2;371(9610):395-403. doi: 10.1016/S0140-6736(08)60203-2.

PMID:
18242413
32.

Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation.

Miranda MB, Redner RL, Johnson DE.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3081-90. Epub 2007 Dec 7.

33.

The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML.

Rush EA, Schlesinger KW, Watkins SC, Redner RL.

Leuk Res. 2006 Aug;30(8):979-86. Epub 2006 Feb 28.

PMID:
16504291
34.

A novel t(3;17)(p25;q21) variant translocation of acute promyelocytic leukemia with rearrangement of the RARA locus.

Redner RL, Contis LC, Craig F, Evans C, Sherer ME, Shekhter-Levin S.

Leukemia. 2006 Feb;20(2):376-9. No abstract available.

PMID:
16341036
35.

Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.

Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner RL, Pandolfi PP.

Oncogene. 2006 Mar 23;25(13):1974-9.

PMID:
16331271
36.

Leukemia fusion proteins and co-repressor complexes: changing paradigms.

Redner RL, Liu JM.

J Cell Biochem. 2005 Apr 1;94(5):864-9. Review.

PMID:
15669080
37.

Variations on a theme: the alternate translocations in APL.

Redner RL.

Leukemia. 2002 Oct;16(10):1927-32. Review.

39.

Involvement of the MLL and RARalpha genes in a patient with acute monocytic leukemia with t(11;17)(q23;q12)

Shekhter-Levin S, Gollin SM, Kaplan SS, Redner RL.

Leukemia. 2000 Mar;14(3):520-2. No abstract available.

41.

Chromatin remodeling and leukemia: new therapeutic paradigms.

Redner RL, Wang J, Liu JM.

Blood. 1999 Jul 15;94(2):417-28. Review. No abstract available.

PMID:
10397708
42.
43.

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM.

Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10860-5.

44.

Isolated deep cerebral venous thrombosis treated by direct endovascular thrombolysis.

Gerszten PC, Welch WC, Spearman MP, Jungreis CA, Redner RL.

Surg Neurol. 1997 Sep;48(3):261-6.

PMID:
9290713
45.
46.

The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ.

Blood. 1996 Feb 1;87(3):882-6.

PMID:
8562957
47.

A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features.

Corey SJ, Locker J, Oliveri DR, Shekhter-Levin S, Redner RL, Penchansky L, Gollin SM.

Leukemia. 1994 Aug;8(8):1350-3.

PMID:
8057672
48.

Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death.

Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS, Pizzo PA.

Medicine (Baltimore). 1992 Jan;71(1):24-43.

PMID:
1549057
49.
50.

Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide.

McManaway ME, Neckers LM, Loke SL, al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, Magrath IT.

Lancet. 1990 Apr 7;335(8693):808-11.

PMID:
1969559

Supplemental Content

Loading ...
Support Center